Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte Lands $40M in Private Placement

NEW YORK (GenomeWeb) – Veracyte today announced that it has entered into a definitive agreement to sell approximately $40 million in stock in a private placement.

Under the terms of the agreement, the investors will purchase 4,907,975 shares of common stock at $8.15 per share, the closing price on April 22, 2015. Investors include Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners, and venBio.

South San Francisco, Calif.-based Veracyte said it intends to use the proceeds for research and development, product commercialization, and general corporate purposes. In fiscal year 2014, the firm's R&D spending rose 68 percent year over year, while SG&A costs increased 67 percent.

Piper Jaffray acted as sole lead placement agent and William Blair & Company acted as a co-placement agent.

Veracyte said it had $25.8 million in cash as of March 31, 2015. 

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.